Summary
Introduction
Headache in its many manifestations, and migraine in particular, form a common and often debilitating series of clinical problems whose pathophysiology is not well understood (Goadsby, 1997; Goadsby and Silberstein, 1997) . Recent therapeutic advances suggesting a role for serotonin (5HT) 1B/1D agonists (Hartig et al., 1996) in the management of acute attacks of migraine (Subcutaneous Sumatripan International Study Group, 1991; Goadsby et al., 1991a) have stimulated interest in this class of compounds and in their mode of action (Humphrey and Goadsby, 1994) . The studies reported here were designed to examine the pharmacology of the trigeminal neurons by locally delivering (3/10 cells) well-characterized 5HT agonists using microiontophoretic techniques. It has been assumed, but never proven that drugs capable of accessing the central nervous system might have their inhibitory actions within the trigeminal nucleus. However, because specific 5HT 1B/1D agonists have never been directly applied to trigeminal neurons, this thesis has not been directly tested.
© Oxford University Press 1997 containing a tungsten recording wire. Signals were amplified and monitored on-line using a custom-written sampling program. Cells were recorded that were activated by electrical stimulation of the sinus and were also spontaneously activated. Cells fired with latencies consistent with Aδ and C fibres, generally firing three or four times per stimulus (0.3 Hz, 250 µs duration, 100 V) delivered to the sinus. Both evoked and spontaneous firing could be inhibited by iontophoresis of ergometrine (9/10 cells), sumatriptan (2/3 cells) and zolmitriptan (9/15 cells) but not by saline
There is little doubt, based on clinical observation, that the pain in migraine in some way involves trigeminal structures (Goadsby and Silberstein, 1997) . Moreover, the longrecognized vascular component of the syndrome has focused attention on the trigeminal innervation of the pain-producing intracranial structures, such as the dura mater and large vessels (Feindel et al., 1960; McNaughton, 1966) . It has been shown during neurosurgical procedures that mechanical or electrical stimulation of these structures in awake humans leads to pain referred to the ophthalmic or first division of the trigeminal nerve (Wolff, 1963) . To obtain a more specific craniovascular stimulus, we have turned from trigeminal ganglion stimulation to intracranial vessels (Goadsby and Zagami, 1991) . The structures chosen, the superior sagittal sinus and middle meningeal artery, have the advantages of being pain-producing in humans (Wolff, 1963) , and being largely innervated by small unmyelinated fibres (Keller et al., 1985) with conduction times in the range of Aδ and C fibres. Stimulation of the superior sagittal sinus has been shown to alter cerebral blood flow in the cat (Lambert et al., 1988) and to lead to changes in neuropeptide levels (Zagami et al., 1990) similar to those seen in humans during migraine Gallai et al., 1995) and cluster headache (Goadsby and Edvinsson, 1994a; Fanciullacci et al., 1995) .
Activation of trigeminal neurons may be studied using a number of techniques. Plasma protein extravasation has been studied as a surrogate of peripheral neuronal activation and has been highly predictive of 5HT 1B/1D agonist activity (Moskowitz and Cutrer, 1993) . However, recent data reporting a clear blockade of trigeminally evoked plasma protein extravasation by the endothelin agonist bosentan (Brandli et al., 1996) , and the NK1 receptor (substance P) antagonists RPR100893 (Lee et al., 1994) and lanepitant (Goldstein and Wang, 1997) , in association with the failure of each compound to arrest the acute attack of migraine (Diener, 1996; May et al., 1996; Goldstein and Wang, 1997) raises the suggestion that additional mechanisms or sites must be involved in the pathophysiology of migraine. Functional anatomical data using both the 2-deoxyglucose method (Goadsby and Zagami, 1991) and the Fos technique have shown that neurons of the trigeminal nucleus descend to the level of C 2 in cat (Kaube et al., 1993b; Hoskin et al., 1996b) and monkey . Although neurons have been located from vascular stimulation in the more rostral trigeminal nucleus Dostrovsky, 1986, 1988) , we have found recording more caudally requires less invasive preparatory surgery and results in a higher yield in identified cells that are in turn well correlated with Fos studies (Hoskin et al., 1996a) .
This study has determined the effect of the 5HT 1B/1D agonists zolmitriptan (311C90) and sumatriptan, and the relatively non-specific agonist ergometrine on activation in the trigeminal system in an animal model of trigeminovascular activation that has considerable functional similarities to migraine (Goadsby et al., 1991b) . Ergometrine was employed as a positive control because receptors binding ergot-related compounds are found in the trigeminal nucleus (Goadsby and Gundlach, 1991) and ergots are inhibitory at these cells (Hoskin et al., 1996a) . Zolmitriptan has been shown to be highly effective in the acute treatment of migraine (Visser et al., 1996) and to inhibit trigeminal neuronal activity when administered intravenously , thus its mode and site of action are of interest. In this study, direct measurements of trigeminal neurons have been made and the effects of locally applied compounds examined.
Methods
All experiments were carried out in a manner consistent with the UK Home Office guidelines. Ten cats weighing 2.7 Ϯ 0.3 kg (mean Ϯ SD) were anaesthetized with α-chloralose (60 mg/kg, intraperitoneally with supplements of 20 mg/kg intravenously; Sigma Chemicals, St Louis, Mo., USA). They were intubated and ventilated (Ugo Basille, Italy) and paralysed with gallamine triethiodide (6 mg/kg, intravenously). The level of anaesthesia was assessed prior to re-dosing. End-expiratory CO 2 and fraction of inspired O 2 were continuously monitored (DATEX, Finland). Polyethylene catheters were also placed into the femoral artery for monitoring blood pressure and into the femoral vein for fluid and drug administration.
Surgery
After the cat was mounted in a stereotactic frame, a circular midline craniotomy (25-mm diameter) and C 1 /C 2 -laminectomy were performed for access to the superior sagittal sinus and the recording site in the C 2 spinal cord, respectively. Possible artefacts from arterial pulsation and respiration were reduced by bilateral pneumothoraces, suspension of the thoracic spinal processes and clamping of the C 1 lateral spinal processes. The dura and falx adjacent to the superior sagittal sinus were dissected over 10 mm and the sinus suspended over bipolar platinum hook electrodes. To prevent dehydration, and for electrical insulation against the cortex, a paraffin bath was built with a dam of dental acrylic around the craniotomy and a small polyethylene sheet inserted under the superior sagittal sinus.
Stimulation and recording
To activate trigeminal primary afferents, the superior sagittal sinus was stimulated with a Grass S88 stimulator connected to a stimulus isolation unit (40-150 V, 250 µs, 0.1-1 Hz; Grass Instruments, Quincy, Mass., USA; SIU5A). Recordings were made using glass-coated tungsten electrodes, six glass micropipettes surrounding the central electrode were used for the microiontophoretic application of test compounds and control substances. After removal of the dura and pia mater from the dorsal surface of the spinal cord, the multibarrelled electrodes were lowered into the spinal cord caudal to the C 2 roots. The microelectrode was advanced or retracted in the cord substance using a piezoelectric microdrive (Burleigh). Bacteriological agar (3% in saline; Difco) was poured over the exposed cord after electrode insertion to reduce cardiovascularly related movements. The tungsten wire electrodes (Ͻ200 kΩ measured at 1 kHz in 0.9% saline) gave good discrimination of units in the cord. Each of the six micropipette iontophoresis barrels of the electrode had impedances of~50 MΩ). A microiontophoresis current generator (Dagan 6400, Dagan Corporation, Minneapolis, Minn., USA) provided the current for injection from the barrels. Retaining and balancing currents were used routinely (Bloom, 1974) . Ejection of sodium or chloride ions from a barrel containing normal saline was used as a control for current injection. Signals from the electrode were fed to a Neurolog preamplifier (Digitimer, Herts, UK) and then via a window discriminator to an A-D converter in a microcomputer. The amplifier bandwidth was usually 300 Hz to 10 kHz. When discriminating between somatic and axonal recordings, an amplifier bandwidth of DC to 30 kHz was used.
In order to record the response of single units to stimulation, post-stimulus histograms were constructed online and saved on disk. Peri-stimulus histograms were used to record spontaneous firing rates. A delay line and averaging routine were used to construct averaged action potentials. Selected single unit sites were marked for subsequent identification with an electrolytic lesion made by passing a 20-25 µA DC cathodal current through the recording electrode for 20-30 s. At the conclusion of the experiment, the animal was given a lethal dose of pentobarbitone, perfused with formalin and the brain removed. The spinal cord was sectioned (50 µm) and recording sites reconstructed, relative to the lesions, from the microdrive readings.
Drugs
Zolmitriptan (311C90; Wellcome Foundation, UK), ergometrine (Sigma Chemicals), sumatriptan (Wellcome Foundation, UK) and DL-homocysteic acid (Sigma Chemicals) were administered iontophoretically using currents of 50-200 nA for periods of 10-60 s.
Analysis
The suppression or activation of cell firing was determined from both peri-stimulus and post-stimulus histograms using the criteria of a shift of ജ30% from baseline. Drug comparisons were made using the Kruskal-Wallis one-way analysis of variance assessing significance at the P Ͻ 0.05 level (Siegel, 1956) .
Results

Stimulus evoked responses
Thirty-eight cells that responded to electrical stimulation of the superior sagittal sinus were identified at the C 2 level of the spinal cord in 10 cats. Their firing characteristics were mainly those of Aδ fibres (latencies of 8-25 ms) with each cell discharging on average 3-4 times per stimulation. Iontophoresis of saline (100 nA) did not significantly affect spontaneous cell firing (Fig. 1) . Iontophoresis of zolmitriptan (50-200 nA) and ergometrine (50-100 nA; Figs 1 and 2) Fig. 1 Suppression of spontaneous firing of a sagittal-sinus-linked C 2 dorsal horn neuron by microiontophoretically applied ergometrine (Ergo; 98 nA, 60 mM), sumatriptan (Suma; 100 nA, 240 mM) and zolmitriptan (Zolmi; 102 nA, 100 mM). Firing was accelerated by DL-homocysteic acid (HCA; 101 nA, 1 M) and unaffected by physiological saline (98 nA). Periods of microiontophoretic application are indicated by bars and the firing rate is plotted for 1-s bins. Fig. 2 Response of 38 cells in the C 2 dorsal horn of the cervical spinal cord to microiontophoretically applied drugs. These cells were responsive to electrical stimulation of the superior sagittal sinus. Neurons responded with Aδ (8-25 ms) and C (100-500 ms) fibre latencies with Aδ being predominant. Cells discharged three to four times in response to supramaximal stimuli. Compounds were applied with currents of 50-200 nA (see Fig. 1 legend for ejection currents). significantly (P Ͻ 0.05) attenuated responses to superior sagittal sinus stimulation (P ϭ 0.03; Fig. 2 ).
Spontaneously active cells
Eight spontaneously active cells were identified that could also be activated by sagittal sinus stimulation. DLHomocysteic acid increased the firing of these spontaneously active cells by 5-18 times. In agreement with the data for stimulus-evoked activity, iontophoresis of saline onto these spontaneously active cells had no significant effect on cell firing, whereas iontophoresis of sumatriptan, zolmitriptan and ergometrine reduced their firing rates (P Ͻ 0.05; Fig. 2) .
Discussion
These data demonstrate that local application of the 5HT 1B/1D agonists, zolmitriptan and sumatriptan, inhibits trigeminal neuronal activity, whereas the excitatory amino acid, DL-homocysteic acid, increases cell firing and saline has no effect. In addition, ergometrine, a non-specific 5HT 1 agonist, shares the inhibitory effect at this site. The experiments demonstrate that there is an inhibitory (probably 5HT 1B/1D ) receptor on these neurons which is capable of reducing trigeminal neuronal traffic and thus the pain information in primary headaches, such as migraine and cluster headache.
These studies rely on the model of superior sagittal sinus stimulation as a system for examining trigeminovascular nociceptive transmission. It is clear in humans that mechanical or electrical stimulation of the superior sagittal sinus in vivo is painful (Ray and Wolff, 1940; Feindel et al., 1960; McNaughton, 1966) . Furthermore, accidental stimulation of the trigeminal ganglion during thermocoagulation for trigeminal neuralgia when anaesthesia is not adequate is extremely painful and well remembered by the few patients who have the experience (P.J.G., unpublished observations). Moreover, patients refer pain from the superior sagittal sinus stimulation to the ophthalmic division of the trigeminal nerve (Wolff, 1963) . Similarly, distension of the large cerebral vessels, middle cerebral or anterior cerebral artery, produces pain referred to the ophthalmic division of the trigeminal nerve (Martins et al., 1993; Nichols et al., 1993) . There is good evidence that there is activation of the trigeminovascular system in migraine, since the neuropeptide marker for that innervation, calcitonin gene-related peptide, is released during migraine attacks Goadsby and Edvinsson, 1993; Gallai et al., 1995) . Superior sagittal sinus stimulation in the cat leads to similar changes in neuropeptides (Zagami et al., 1990 ). The sinus model, therefore, acts as an excellent method by which to examine aspects of the trigeminovascular system that cannot be studied in humans.
By stimulation of the sinus with a hook electrode, the trigeminal nerves innervating the sinus are directly activated. This avoids the nerve-vessel interface and, therefore, the peripheral 5HT 1B/1D receptor (Hartig et al., 1996) that mediates neurogenically evoked plasma protein extravasation in the dura mater (Moskowitz and Cutrer, 1993) . It is highly unlikely that neurogenic plasma extravasation plays an important role in trigeminal neuronal activation in the sagittal sinus model since the highly specific inhibitor of that process CP122,288 (Gupta et al., 1995) does not inhibit sagittal sinus evoked trigeminal nucleus activity . The remaining site for the action of the test compound must be within the trigeminal nucleus at the first order synapse. The only intervening structures are the axons of passage and the cell bodies of the trigeminal ganglion, neither of which are known to have functional 5HT 1B/1D receptors (O'Shaughnessy et al., 1993) . We have seen in the same model that trigeminal evoked potentials are not altered by sumatriptan administration unless the blood-brain barrier is disrupted (Kaube et al., 1993a) . Furthermore, using the Fos model sumatriptan inhibits trigeminal nucleus activation only after blood-brain barrier disruption (Shepheard et al., 1995) . These studies demonstrate that a population of sumatriptan-activated receptors can be found in the trigeminal nucleus that would not normally be activated by the drug because of its hydrophilicity (Humphrey et al., 1991) . It has been shown that the ergotamine derivative, dihydroergotamine, has both access to (Goadsby and Gundlach, 1991) , and potent effects at (Hoskin et al., 1996a) , trigeminal nucleus cells after intravenous administration. Moreover, dihydroergotamine is clearly a potent compound in the clinic (Winner et al., 1996) . Its pharmacology is identical to ergometrine which we have used in these studies because it is easier to solubilize for iontophoresis than dihydroergotamine (Lambert et al., 1992) . It could be expected from its chemistry (Martin, 1994; Rance et al., 1997) that zolmitriptan would have access to the trigeminal nucleus just as does dihydroergotamine.
Consistent with these clinical data it has been reported that a central reflex activation of the parasympathetic nervous system in the cat evoked by sagittal sinus stimulation (Goadsby and Edvinsson, 1994b) and trigeminal neuronal activity in the cat, again evoked by sagittal sinus stimulation, could both be blocked by intravenous administration of zolmitriptan . Moreover, the similarly lipophilic 5HT 1B/1D agonist rizatriptan also inhibits trigeminal activity after intravenous administration (Cumberbatch et al., 1996) . The data in this study demonstrate that local application of 5HT 1B/1D agonists specifically to trigeminal nucleus cells inhibits their evoked activity and spontaneous firing. Because of the highly localized nature of iontophoretic application and its relatively short-lasting effects, it is clear that the actions of the compounds tested are within the nucleus. These data demonstrate conclusively for the first time that there are functional 5HT 1B/1D receptors in the trigeminal nucleus.
The data presented do not completely answer the question of which of the 5HT 1 receptors (Hoyer et al., 1994; Hartig et al., 1996) is responsible for the inhibitory effects observed. Both zolmitriptan (Martin, 1994) and sumatriptan (Humphrey et al., 1991) are 5HT 1B/1D agonists, as are the ergot-derivatives (Hamblin et al., 1987) . The ergot-derivatives are potent at the 5HT 1A site (Hamblin et al., 1987) , while sumatriptan is weakly potent, and zolmitriptan even less potent, at that site. Following this argument it is of interest that zolmitriptan is inactive at the 5HT 1E site which effectively excludes it in mediating this inhibitory effect. Since both zolmitriptan and sumatriptan are active at the 5HT 1F site, a compound with good 5HT 1B/1D activity but no 5HT 1F activity is required to exclude this site. Compounds have now been synthesized that are either specific 5HT 1F agonists, such as LY334370 (Phebus et al., 1996) , or 5HT 1B/1D agonists devoid of 5HT 1F agonist actions, such as alniditan (Leysen et al., 1996) . Alniditan is in clinical trial (Goldstein et al., 1996) , and the 5HT 1F agonists have just started clinical trials, and these compounds will assist in differentiating the precise nature of the trigeminal inhibitory receptor. Autoradiographic data do not assist in differentiating this site since [ 3 H]sumatriptan binding is seen in cat (Mills and Martin, 1995) , guinea pig (Waeber and Moskowitz, 1995) and humans (Pascual et al., 1996) , and [ 3 H]zolmitriptan binding in the cat (Goadsby and Knight, 1997) .
In summary, these data have demonstrated a clear inhibition of trigeminal cell firing with microiontophoretic application of the 5HT 1B/1D agonists zolmitriptan and sumatriptan. This is seen in spontaneously active cells that respond to sagittal sinus stimulation and in cells only responding to stimulation. The inhibition is robust, time-locked and reproducible. Given the pharmacological profile of the drugs used, the 5HT 1F receptor, or an as yet uncharacterized receptor, cannot be excluded to have a role. The data conclusively demonstrate for the first time that this class of compounds can have local functionally significant effects in the trigeminal nucleus since the method of microiontophoresis effectively excludes actions at distant sites. The data provide further evidence that a neuronally selective compound, not necessarily active against plasma protein extravasation, and with access to the trigeminal nucleus, would be likely to have a role as an abortive agent in migraine.
